drugset / Trial / NCT03723031

Intrauterine Misoprostol Versus Rectal Misoprostol in Reducing Blood Loss During Cesarean Section

NCT03723031

Phase 2 Unknown 98 enrolled Cairo University
RandomizedParallel-groupSingle-blindPrevention

Summary

98 pregnant women attending for CS will be randomized into 2 groups. Rectal misopristol group who will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion and intrauterine misopristol group will receive 400 microgram misoprostol intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta. The estimated blood loss for each patient will be measured and data of both groups will be compared.

Timeline

Start
2018-11-15
Primary completion
2020-04-15
Completion
2020-05-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Misoprostol Other / unclassified 400 ug Rectal

Indications